{"denomUnitsSelected":"Participants","description":"Time to progression is defined as the time from randomization to progression. Patients without documented progression will be censored at date of last disease assessment.\n\nProgression is defined as one of the following criteria is met.\n\n* Increase of ≥ 25% from lowest value reported in serum M-component (the absolute increase must be ≥ 0.5 g/dL) and/or urine M-component (the absolute increase must be ≥ 200 mg/ 24 hours).\n* Only in patients without measurable serum and urine M protein levels: the difference between involved and uninvolved FLC levels. The absolute increase must be \\> 10 mg/dL.\n* If the only measurable disease is bone marrow, bone marrow plasma cell percentage: the absolute % must be ≥ 10%.\n* Development of new bone lesions or soft tissue plasmacytomas or ≥ 50% increase from nadir in the size (SPD) of existing bone lesions or soft tissue plasmacytoma or ≥ 50% increase in the longest diameter of a previous lesion \\> 1cm in short axis.","reportingStatus":"NOT_POSTED","timeFrame":"Assessed every 3 months if patient is <2 years from randomization, every 6 months if patient is 2-5 years from randomization, annually if patient is 5 years or more from randomization.","title":"Time to Progression","type":"OTHER_PRE_SPECIFIED"}